SLNO
Soleno Therapeutics, Inc.NASDAQHealthcare$39.49+32.31%ClosedMarket Cap: $2.12B
As of 2026-04-06
Valuation
P/E (TTM)
101.53
PEG
0.91
P/B
6.17
P/S
14.74
EV/EBITDA
96.50
DCF Value
$169.01
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.6%
Operating Margin
5.4%
Net Margin
11.0%
ROE
5.9%
ROA
3.7%
ROIC
2.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $91.7M | 99.1% | $40.4M | $43.4M | $0.80 | — |
| FY 2025 | $190.4M | 98.6% | $14.9M | $20.9M | $0.39 | — |
| Q3 2025 | $66.0M | 98.3% | $22.1M | $26.0M | $0.47 | — |
| Q2 2025 | $32.7M | 97.9% | $-6.5M | $-4.7M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-45.7M | $-43.8M | $-0.95 | — |
| Q4 2024 | $0.00 | NaN% | $-59.1M | $-56.0M | $-1.27 | — |
| FY 2024 | $0.00 | NaN% | $-187.7M | $-175.8M | $-4.38 | — |
| Q3 2024 | $0.00 | NaN% | $-80.2M | $-76.6M | $-1.83 | — |
| Q2 2024 | $0.00 | -Infinity% | $-23.2M | $-21.9M | $-0.57 | — |
| Q1 2024 | $0.00 | NaN% | $-23.5M | $-21.4M | $-0.59 | — |
| Q4 2023 | $0.00 | NaN% | $-13.9M | $-11.3M | $-0.43 | — |
| FY 2023 | $0.00 | NaN% | $-41.4M | $-39.0M | $-2.36 | — |